In a dramatic turn in the pharmaceutical world, AbbVie has filed a lawsuit against BeiGene, alleging the theft of trade secrets related to a cutting-edge cancer treatment. The lawsuit, lodged in a Chicago federal court, accuses BeiGene of leveraging confidential information stolen from AbbVie to fast-track the development of its own cancer-fighting drug.
AbbVie claims that it invested significant time and resources into creating a groundbreaking compound aimed at treating cancers linked to B cells, which are crucial for immune responses. Central to the dispute is a drug known as a “BTK degrader,” designed to target and eliminate a specific molecule involved in B cell growth.
The heart of the accusation revolves around BeiGene’s alleged recruitment of Huaqing Liu, a former AbbVie scientist with deep involvement in their BTK degrader program. AbbVie asserts that BeiGene enticed Liu to use his insider knowledge to advance their own BTK degrader project. Liu has been named as a defendant in the lawsuit.
In response, BeiGene has vehemently denied the claims, asserting that the lawsuit is a strategic maneuver to hinder their progress. The company points out that it had filed for patents on its BTK degrader, BGB-16673, before AbbVie filed for its own patents. Furthermore, BeiGene’s drug has recently been granted “fast track” status by the U.S. Food and Drug Administration and is currently under study for treating leukemia and lymphoma.
The legal battle continues as AbbVie seeks unspecified damages and an injunction to safeguard its trade secrets and proprietary information. The case is officially titled AbbVie v. BeiGene Ltd et al, filed in the U.S. District Court for the Northern District of Illinois.
